Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion – Head and neck cancer

5959 - Efficacy Evaluation of Optimal Patient Selection for Hypopharyngeal Cancer Organ Preservation Therapy using MRI-derived Radiomic Signature: Bi-institutional Propensity Score Matched Analysis

Date

28 Sep 2019

Session

Poster Discussion – Head and neck cancer

Presenters

Shih-min Lin

Citation

Annals of Oncology (2019) 30 (suppl_5): v449-v474. 10.1093/annonc/mdz252

Authors

S. Lin1, C. Hsu2, Y. Lee3, T. Li4, S. Kuo5, W. Wang6

Author affiliations

  • 1 Radiation Oncology, Chang Gung Medical Foundation - Linkou Chang Gung Memorial Hospital, 33305 - Taoyuan City/TW
  • 2 Department Of Oncology, National Taiwan university hostipal, 10048 - Taipei/TW
  • 3 Mathematics, National Taiwan University, 10617 - Taipei/TW
  • 4 Radiation Oncology, National Taiwan University Hospital, 10002 - Taipei City/TW
  • 5 Department Of Oncology, National Taiwan University Hospital, 10002 - Taipei City/TW
  • 6 Institute Of Applied Mathematical Sciences, National Taiwan University, 10617 - Taipei/TW

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5959

Background

Early loco-regional failure (LRF) after organ preservation therapy (OPT) varies widely for hypopharyngeal squamous cell carcinoma (HPSCC) patients. We aim to develop and validate a MRI-derived radiomic signature RS for the prediction of 1-year LRF in HPSCC treated with OPT, and investigate its efficacy between OPT and total laryngectomy (TL) cohort.

Methods

A total of 3912 MRI-based radiomic features (RF) of pretreatment tumors were obtained from 370 HPSCC patients, including OPT cohort1 (OPT1; n = 186), OPT cohort2 (OPT2; n = 88), and TL cohort (TLc; n = 96). Variational autoencoder (VAE), trained with symmetric two encoded and decoded layers of neural network was applied to reduce the dimensionality of original RF to 128 VAE-RF. Least absolute shrinkage and selection operator with 10-fold cross validation performs features selection and constructs RS to predict 1-year LRF events in OPT1, which was validated in OPT2 and TLC. Harrell’s C-index was used to evaluate the discriminative ability of RS. Optimal cut-point for dichotomized RS risk category was determined via Youden index. Pair-wise propensity score matching (caliper 0.2) using pre-treatment variables (age, gender, TNM stage) was applied to compare the impact of OPT and TL under different RS risk categories.

Results

The RS yielded 1000 times bootstrapping corrected C-index of 0.753, 0.745 and 0.398 in the OPT1, OPT2 and TLC, respectively. Dichotomized risk category using Youden cut-point of RS yielded 1 year LRF predictive accuracy of 71.12%, 70.41%, and 41.74% in OPT1, OPT2 and TLC, respectively. In RS-high risk group, OPT were associated with poor progression-free survival (PFS, HR: 1.752, p = 0.032), while in RS-low risk group, OPT did not deteriorate the PFS (HR: 0.774, p = 0.416).

Conclusions

The RS-based model provides a novel to predict 1-year LRF and survival in patients with HPSCC who received OPT. The prediction performance discrepancy of MRI-derived RS in TLC also emphasizes the role of TL in RS-high risk group.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.